The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

In patients with cardiac amyloidosis, renal infarction is associated with acute kidney injury according to a new study in Mayo Clinic Proceedings, published by Elsevier.

Acute kidney injury in a context of cardiac amyloidosis may be due to renal infarction, report scientists in a new study published in Mayo Clinic Proceedings Rochester, MN, May 15, 2019 - Systemic ...

First study of its kind finds renal infarction in cardiac amyloidosis may be more common than previously thought, especially in patients with acute kidney injury, but an expert questions the results.

For patients with acute MI at increased risk for HF, empagliflozin showed cardiorenal benefits and was safe to initiate early ...

The presence of silent cerebral infarction (SCI) may predict an increased risk for worsening kidney function in patients with type 2 diabetes.

Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with acute myocardial infarction (MI), according to a study published ...

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

Advanced CKD was linked to a higher likelihood of both fatal and non-fatal adverse outcomes after acute myocardial infarction treatment. Patients with advanced chronic kidney disease (ACKD) with ...

Acute renal infarction is a rare, yet potentially devastating condition marked by the sudden interruption of blood supply to the renal parenchyma, often resulting in irreversible tissue damage ...

Total adverse events of heart failure or all-cause mortality were reduced with empagliflozin, regardless of kidney function.